Molbio Diagnostics Shares List at 21% Premium Following Strong IPO Subscription
Molbio Diagnostics debuted on the stock market on August 17, listing at Rs 980 per share, a 21.44% premium over its Rs 807 IPO price. The Rs 940 crore IPO, comprising a Rs 200 crore fresh issue and Rs 740 crore offer for sale, was subscribed 70.26 times, led by strong institutional demand. The company plans to use proceeds for R&D infrastructure, manufacturing expansion, and general corporate purposes. Despite initial profit-booking, the listing exceeded grey market expectations, reflecting investor confidence in Molbio's growth prospects.
First-hand measurement across 8 sources
We measured how 8 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 42/100.
Outlets measured: news18, businessstandard, mint, businessstandard, moneycontrol, economictimes, moneycontrol, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 16 Aug, 10:32 am. Other outlets followed.